bronchitol declined by pbs , page-12

I'm not surprised really, I talked about PBS issues here weeks ago. Issues regarding the previous rejection have clearly yet to be addressed by the company.

Successful EU marketing approval should have no bearing on AU PBS approval and rightly so. The fact that this is an Aussie company should also have no influence on PBS approval.

Government subsidies for private drugs using public funds should only be judged on the cost/benefit society derives from them.

There is limited funds available for new government subsidies at the moment and this is an extremely expensive drug that requires a lifetime of treatment.

My pick is that without new trial results or a generous discount for government's wishing to subsidise this drug, Bronchitol won't be making PBS listing any time soon.

IMHO the future for Bronchitol is still bright though because CF sufferers have extremely few alternatives, however don't expect governments will be rushing out to subsidise this drug without further developments.